N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases
| Autor: | Mary Holmay, Melissa Terpstra, Paul J. Tuite, Matthew Ahlskog, Usha Mishra, Gülin Öz, James C. Cloyd, Lisa D. Coles |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Antioxidant Adolescent medicine.medical_treatment Pharmacology Antioxidants Article Antiparkinson Agents Acetylcysteine chemistry.chemical_compound Downregulation and upregulation medicine Humans Pharmacology (medical) Dosing Infusions Intravenous Neurons Gaucher Disease medicine.diagnostic_test business.industry Brain Parkinson Disease Magnetic resonance imaging Human brain Glutathione Middle Aged Magnetic Resonance Imaging Up-Regulation Peripheral Kinetics medicine.anatomical_structure chemistry Biochemistry Female Neurology (clinical) business Oxidation-Reduction medicine.drug |
| Zdroj: | Clinical Neuropharmacology. 36:103-106 |
| ISSN: | 0362-5664 |
| Popis: | Objective This study aimed to determine if the antioxidant N-acetylcysteine (NAC) is able to alter peripheral and central redox capabilities in patients with Parkinson disease (PD) or Gaucher disease (GD). Methods The study included nondemented adult subjects: 3 with PD, 3 with GD, and 3 healthy controls. Baseline brain glutathione (GSH) concentrations were measured using 7-T magnetic resonance spectroscopy (MRS). Baseline blood reduced-to-oxidized GSH ratios were determined for each subject. Brain GSH concentrations and blood redox ratios were then determined during and at specified time points after a single, 150-mg/kg NAC infusion. Results N-acetylcysteine increased blood GSH redox ratios in those with PD and GD and healthy controls, which was followed by an increase in brain GSH concentrations in all subjects. Conclusions This is the first demonstration that with MRS, it is possible to directly measure and monitor increases in brain GSH levels in the human brain in response to a single, intravenous administration of NAC. This work shows the potential utility of MRS monitoring, which could assist in determining dosing regimens for clinical trials of this potentially useful antioxidant therapy for PD disease, GD, and other neurodegenerative disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|